Kiadis Pharma Raises EUR 10 Million in Financing Round

Amsterdam, The Netherlands, November 20, 2012 – Kiadis Pharma B.V., a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing treat­ments for blood can­cers, announced today that it has raised EUR 10 mil­lion in an equi­ty financ­ing round.
This round was led by the Company’s largest share­hold­er LSP (Life Sciences Partners) and sup­port­ed by a large invest­ment from DFJ-Esprit. Other investors includ­ed Alta Partners, Quest for Growth, and NOM. The financ­ing will enable Kiadis Pharma to per­form a con­fir­ma­to­ry mul­ti-cen­ter Phase II proof-of-con­cept study with its lead prod­uct ATIR™, and to pre­pare a piv­otal Phase II/III study.
Manfred Ruediger, PhD, CEO of Kiadis Pharma, com­ment­ed: “We are delight­ed with the enthu­si­as­tic sup­port from exist­ing and new investors, which attests to the excit­ing clin­i­cal data gen­er­at­ed for ATIR™ so far and to the progress the Company has achieved over the last year. We are deter­mined to advance ATIR™ in close coop­er­a­tion with our clin­i­cal inves­ti­ga­tors in North America and Europe.”

About ATIR™
ATIR™ is a cell based med­i­c­i­nal prod­uct can­di­date enabling stem cell trans­plan­ta­tions from mis­matched (hap­loiden­ti­cal) fam­i­ly donors to patients suf­fer­ing from blood can­cer. Stem cell trans­plan­ta­tion is the only poten­tial­ly cura­tive option for many patients but a match­ing donor is avail­able for only half of the patients in need. ATIR™ thus has the poten­tial to address this unmet need and to make stem cell trans­plan­ta­tions avail­able for patients world­wide. Those T-cells in a hap­loiden­ti­cal graft which would cause Graft-ver­sus-Host-Disease (GvHD) are selec­tive­ly elim­i­nat­ed using pro­pri­etary tech­nol­o­gy to pro­duce ATIR™. ATIR™ is admin­is­tered as an adjunc­tive treat­ment on top of a hap­loiden­ti­cal stem cell trans­plan­ta­tion enhanc­ing ear­ly immune recon­sti­tu­tion with­out caus­ing GvHD.
In a Phase I/II study with ATIR™, safe­ty and proof of con­cept were pro­vid­ed in terms of absence of grade III/IV GvHD, reduced rates of infec­tion, reduced Transplant Related Mortality and improved Overall Survival. ATIR™ has been grant­ed Orphan Drug Designation both in the EU and the USA. Together, both regions rep­re­sent a com­bined pri­ma­ry mar­ket poten­tial of more than EUR 1 bil­lion per year.

Leave a Reply

Your email address will not be published. Required fields are marked *